Vol. 22/No. 03 | OncologyLive

Bad Company: Concurrent Mutations Define Unique Subsets of NSCLC

February 18, 2021

The identification of oncogenic driver mutations in non–small cell lung cancer to inform targeted therapy selection is the bedrock of clinical practice in this disease, with current estimates suggesting that more than half of patients harbor an actionable mutation.

Monoclonal Antibodies Prove to Be Novel Therapeutics for Myeloma

February 12, 2021

Novel drugs have especially improved the treatment options for relapsed myeloma, with some agents now also being used as frontline therapy. As a result, outcomes for patients with newly diagnosed and relapsed disease continue to improve with prolongation of median survival to greater than 7 years from diagnosis.

Cancer Staging and Toxicity Framework Should Be Overhauled for the Modern Era

February 08, 2021

Formerly, small cell lung cancer was generally considered more chemotherapy sensitive in the short term but also associated with an overall inferior survival outcome; however, the difference in prognosis compared with metastatic non–small cell lung cancer was measured in months—rarely longer.